



# Evidence of Budget Accuracy & Reliability

## STUDY BUILD ASSESSMENT

SMALL, MID-COMPLEXITY, PHASE 2 CNS STUDY  
LEADING JAPANESE PHARMA

The Sponsor provided key assumptions from a recently non-competitively sourced study in an excel file. No protocol or study design was provided. The study was modeled as medium complexity using Clinical Maestro's PORTFOLIO application for planning and budgeting.

## STUDY DESCRIPTION

- Phase 2
- Therapy Area: CNS
- Indication: Treatment-Resistant Depression
- US only
- 12 Sites
- 138 Patients Screened
- 90 Patients Enrolled
- 81 Patients Completed

## RESULTS

With limited context provided by the Sponsor (no protocol, bid grid, tasks and responsibilities), the study budget built using Clinical Maestro was calculated to be \$3,115,478 in direct fees. This presents a 3.8% variance from the awarded budget (Top Tier CRO).

## CONCLUSIONS

Clinical Maestro's budget simulation tool predicted the study cost range with near 100% accuracy.

The reliability of benchmarking and ease of use makes Clinical Maestro an ideal tool for efficient modelling of mid-complexity studies and strategic management of non-competitive bidding.



# 2

### Hours of Effort

to create the study budget and scenarios in Clinical Maestro

# 4

### Scenarios Built

Ranged from \$2.8M to \$3.1M depending on complexity and service assumptions

# +3.8%

### Variance

between Awarded CRO budget and Clinical Maestro calculated budget



New Ways to Solve Old Problems

For more information or to request a proposal, please contact:

Farah Ahmad  
Chief Commercial Officer  
514.978.1112  
[fahmad@strategikonpharma.com](mailto:fahmad@strategikonpharma.com)